VSee Health (NASDAQ: VSEE) investors back private placement share issuance

Rhea-AI Filing Summary

VSee Health, Inc. reported that stockholders approved a key share issuance related to a private placement at a special meeting held on March 2, 2026. The meeting had a quorum, with 21,824,877 votes represented, or 50.46% of shares entitled to vote.

Stockholders approved issuing common shares to certain holders of warrants to purchase up to 19,672,130 shares of common stock, as required under Nasdaq Listing Rule 5635(d). The proposal passed with 14,109,726 votes for, 7,698,963 against, and 16,188 abstentions. An adjournment proposal was also approved but withdrawn because the main private placement proposal received sufficient support.

false 0001864531 0001864531 2026-03-02 2026-03-02 0001864531 VSEE:CommonStock0.0001ParValuePerShareMember 2026-03-02 2026-03-02 0001864531 VSEE:WarrantsWhichEntitlesHolderToPurchaseOne1ShareOfCommonStockAtPriceOf11.50PerWholeShareMember 2026-03-02 2026-03-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 2, 2026

VSEE HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41015		86-2970927
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

980 N Federal Hwy #304 Boca Raton, Florida		33432
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (561) 672-7068

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		VSEE		The Nasdaq Stock Market LLC
Warrants, which entitles the holder to purchase one (1) share of common stock at a price of $11.50 per whole share		VSEEW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On March 2, 2026, VSee Health, Inc., a Delaware corporation (the “Company”), held a special meeting of stockholders (the “Special Meeting”). As of February 2, 2026, the record date for the Special Meeting, there were 43,244,355 shares of common stock, par value $0.0001 per share (“Common Stock”), outstanding, which shares were entitled to an aggregate of 43,244,355 votes at the Special Meeting and 1,559 shares of Series A Preferred Stock, par value $0.0001 per share (the “Preferred Stock”), which shares were entitled to 155,900 votes at the Special Meeting. Holders of 21,824,877 shares of the Company’s capital stock entitled to vote were present in person or by proxy at the Special Meeting, representing 50.46% of the total outstanding shares of capital stock entitled to vote, constituting a quorum pursuant to the Company’s bylaws, as amended. At the Special Meeting, two proposals were submitted to the Company’s stockholders. A brief summary of the matters voted upon by stockholders at the Special Meeting is set forth below, and the proposals are described in more detail in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on February 5, 2026, as supplemented on February 17, 2026 (the “Proxy Statement”). The voting results reported below are final.

Proposal 1: The Private Placement Proposal

The Company’s stockholders approved, in accordance with the Nasdaq Stock Market, LLC (“Nasdaq”) Listing Rule 5635(d), the issuance of shares of the Company’s Common Stock to certain holders of warrants to purchase up to 19,672,130 shares of Common Stock, as detailed in the Proxy Statement, based upon the following votes:

FOR				AGAINST				ABSTAIN
	14,109,726				7,698,963				16,188

Proposal 2: The Adjournment Proposal

The Company’s stockholders approved of a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there were insufficient votes for, or otherwise in connection with, the approval of any of the foregoing proposals, based upon the following votes:

FOR				AGAINST				ABSTAIN
	18,629,017				3,094,386				101,474

This proposal was withdrawn because the Company’s stockholders approved and adopted the Private Placement Proposal, as noted above.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 3, 2026	VSEE HEALTH, INC.
	By:	/s/ Milton Chen
	Name:	Milton Chen
	Title:	Co-Chief Executive Officer

2

FAQ

What did VSEE stockholders approve at the March 2, 2026 special meeting?

VSee Health stockholders approved issuing common shares in connection with a private placement to certain warrant holders. This approval satisfies Nasdaq Listing Rule 5635(d) requirements and allows the company to honor warrants to purchase up to 19,672,130 common shares.

How many votes supported VSEE’s private placement share issuance proposal?

The private placement proposal received 14,109,726 votes for, 7,698,963 votes against, and 16,188 abstentions. These results meant stockholders approved the issuance of common shares to certain warrant holders, meeting the Nasdaq Listing Rule 5635(d) standard for stockholder approval.

What was the quorum at VSEE’s March 2, 2026 special stockholder meeting?

Holders of 21,824,877 shares were present in person or by proxy, representing 50.46% of the company’s capital stock entitled to vote. This level of participation met quorum requirements under VSee Health’s bylaws, allowing the special meeting to conduct official business.

How many VSEE shares were entitled to vote at the special meeting?

A total of 43,244,355 common shares and 1,559 Series A preferred shares were entitled to vote, with the preferred shares carrying 155,900 votes. Together, these securities formed the full voting power eligible to participate in the March 2, 2026 special meeting.

What happened to the adjournment proposal at VSEE’s special meeting?

Stockholders approved the adjournment proposal, with 18,629,017 votes for, 3,094,386 against, and 101,474 abstaining. However, the company withdrew this proposal because the main private placement proposal had already been approved by stockholders and additional solicitation was unnecessary.

Why did VSee Health need stockholder approval for issuing shares to warrant holders?

VSee Health sought approval to comply with Nasdaq Listing Rule 5635(d), which can require stockholder consent for certain private issuances of common stock. Approval allows the company to issue common shares to designated warrant holders as described in its definitive proxy statement.

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.8 KB
• EX-101 XBRL DEFINITION FILE 26.1 KB
• EX-101 XBRL LABEL FILE 36.1 KB
• EX-101 XBRL PRESENTATION FILE 24.8 KB